EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) - Trial NCT06401421
Access comprehensive clinical trial information for NCT06401421 through Pure Global AI's free database. This phase not specified trial is sponsored by Exact Sciences Corporation and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 1800 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Exact Sciences Corporation
Timeline & Enrollment
N/A
May 01, 2024
Apr 01, 2030
Primary Outcome
Core biopsy tissue evaluability rate,Distant Recurrence Free Interval (dRFI)
Summary
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo
 chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood
 specimens for circulating tumor DNA (ctDNA) analysis.
 
 Participants will be followed for up to 5.5 years.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06401421
Non-Device Trial